Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001508526 | SCV001714743 | likely pathogenic | not provided | 2020-08-12 | criteria provided, single submitter | clinical testing | PVS1_Strong, PM2 |
Ambry Genetics | RCV003161038 | SCV003866196 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-12-09 | criteria provided, single submitter | clinical testing | The c.2186delT pathogenic mutation, located in coding exon 15 of the APC gene, results from a deletion of one nucleotide at nucleotide position 2186, causing a translational frameshift with a predicted alternate stop codon (p.L729Pfs*32). This alteration has been observed in at least one individual with a personal and/or family history that is consistent with APC-related disease (Ambry internal data). This alteration occurs in the last exon of the APC gene and is not expected to trigger nonsense-mediated mRNA decay. However, the impacted region is considered as critical for protein function (Ambry internal data). In addition, this variant disrupts the protein upstream of other pathogenic premature truncating variants. As such, this alteration is interpreted as a disease-causing mutation. |